1999 Resident Poster Competition
Khaldoon Alaswad M.D.
Univ. of Missouri--Kansas City
Effects of Phenytoin,Niacin,Gemfibrozil and Omega-3 Fatty Acids on HDL in Patients With Hypoalphalipoproteinemia
| Third Place Research Division |
Background: Low levels of high density lipoprotein cholesterol (HDL-C) are a known risk factor for CAD. Several drugs are known to be able to raise HDL-C levels, but single-study comparison of several drugs has rarely been made. Here we evaluated the effects of niacin, phenytoin, omega-3 fatty acids, and gemfibrozil on levels of HDL-C and its subfractions (HDL2-C and HDL3-C) in patients with low HDL-C levels.
Methods: Fifty-four patients with HDL-C of 35 mg/dl or less were randomly assigned to three months of blinded treatment with one of four different drugs or placebo.
Results:The statistically significant changes (vs. placebo) in HDL-C and Trig were as follows: Niacin increased HDL-C by 28% (32± 6.3 to 40.8 ± 7.7 mg/dl; p=0.0001), HDL3-C and HDL2-C by 18%, 48%, respectively (p<0.0005), and decreased TG by 43.5%(203 ± 92 to 115 ± 36; p=0.002). Phenytoin increased HDL2-C by 16% (7.9 ± 2.2 to 9.2 ± 2.78; p=0.004). Omega-3 fatty acids increased HDL2-C by 19% (7.6 ± 1.6 to 9.0 ± 2.4; p=0.018), and lowered trig by 24% (p=0.02). Gemfibrozil raised both HDL-C by 17% (32.1 ± 3.7 to 37.4 ± 8.6; p=0.02) and HDL30C by 17% (24.4 ± 3.5 to 28.5 ± 5.2; p=0.02). Triglycerides was reduced by 49% (p=0.005).
Conclusion: The most effective drug for low HDL-C in this group of patients was niacin.
Return to 1999 Table of Contents
What's New
Contact Information
Alan D Forker, MD MACP
Missouri Chapter Governor
Patrick Mills
Missouri Chapter Executive Director
